Skip to main
ADUS
ADUS logo

Addus HomeCare (ADUS) Stock Forecast & Price Target

Addus HomeCare (ADUS) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 63%
Hold 0%
Sell 13%
Strong Sell 0%

Bulls say

Addus HomeCare Corp demonstrates a positive financial outlook, supported by an expected 2.6% increase in Medicare Hospice rates effective October 2025, which may enhance revenue for its Hospice segment. The company's impressive organic revenue growth rates, showcasing +12.3% year-over-year in 2023, +7.7% in 2024, and +7.4% year-to-date in 2025, indicate robust demand for its personal care services in a post-pandemic environment. Additionally, anticipated growth in the Hospice segment, projected at +5% to +7%, alongside potential merger and acquisition activities, signals further opportunities for revenue expansion and operational improvements.

Bears say

Addus HomeCare Corp faces a negative outlook primarily due to same-store declines driven by administrative bottlenecks related to Medicaid redeterminations, resulting in higher patient discharges compared to admissions. Approximately 97% of the company's segment revenues for 2025 year-to-date stem from the uncertain future of Medicaid funding, particularly in light of the legislative impacts from the One Big Beautiful Bill Act (OBBBA). Despite stable operational execution and a favorable long-term demand backdrop, the company's stock has not kept pace with the broader post-acute care sector, indicating a disconnect between equity valuation and the fundamental challenges it faces.

Addus HomeCare (ADUS) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Addus HomeCare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Addus HomeCare (ADUS) Forecast

Analysts have given Addus HomeCare (ADUS) a Buy based on their latest research and market trends.

According to 8 analysts, Addus HomeCare (ADUS) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Addus HomeCare (ADUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.